SVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Savara Inc (SVRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong insider buying trends, a positive analyst rating with an increased price target, and potential upside with its upcoming drug launch. Despite the lack of recent news and weak technical indicators, the long-term growth prospects and insider confidence make it a favorable choice.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is at 67.71, in the neutral zone, showing no overbought or oversold conditions. Moving averages are converging, suggesting no clear trend. The current price is near resistance level R1 (5.843), with the next resistance at R2 (6.056).
Insider buying has increased by 373.33% over the last month, showing strong insider confidence.
Analyst Andrew Fein raised the price target from $8 to $10 and maintained a Buy rating, citing the company's strong positioning ahead of a potential drug launch.
The stock has a 22.67% chance of increasing in the next month based on candlestick pattern analysis.
Weak technical indicators with no clear upward momentum.
No recent news or event-driven catalysts.
The stock has a 40% chance of dropping 3.6% in the next week.
In Q3 2025, the company reported no revenue growth (0% YoY), but net income improved by 21.91% YoY to -$29.56M. EPS also improved by 27.27% YoY to -0.14. Gross margin remains at 0%. While the company is not yet profitable, the financials show signs of improvement.
H.C. Wainwright analyst Andrew Fein raised the price target from $8 to $10 and maintained a Buy rating, citing the company's strong positioning ahead of a potential drug launch.
